February 08, 2018
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Webcast Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 8, 2018--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W.
Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief
Scientific Officer, and Robin L. Washington, Gilead’s Executive Vice
President and Chief Financial Officer, will participate in a fireside
chat at the RBC Capital Markets 2018 Global Healthcare Conference in New
York on Wednesday, February 21 at 9:00 a.m. Eastern Time.
The audio portion of the fireside chat will be accessible live through
the company’s Investors page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be required to listen to the webcast. The replay will
be available for 14 days following the presentation.
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208006049/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792